Actively Recruiting
Phase I Study to Assess Safety, Tolerability, and How RSS0343 Is Processed in Healthy Adults Aged 18 to 55
Led by Reistone Biopharma Company Limited · Updated on 2026-01-14
48
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety, tolerability, and how the body processes RSS0343 after multiple oral doses in healthy adults aged 18 to 55 years. This phase I clinical trial also monitors the effects of RSS0343 on heart electrical activity, specifically the QTQTc interval. Participants will receive either RSS0343 tablets or placebo tablets, taken orally, in a randomized and double-blind manner. The study observes the effects over a 28-day period, assessing the drugs concentration in the blood at various times and its elimination from the body. During the study, participants will undergo physical exams, vital signs checks, lab tests, and heart monitoring. Researchers will track any adverse events, measure drug levels in blood and urine, and monitor changes in heart rhythm. The study includes close safety monitoring throughout the 28-day evaluation period.
CONDITIONS
Brief Title
A Clinical Study of RSS0343 in Healthy Subjects
Research Team
Y
Ye Xu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
